


CYPROHEPTADINE HYDROCHLORIDE- cyproheptadine hydrochloride tablet Apnar Pharma

Cyproheptadine Hydrochloride Tablets, USP

DESCRIPTION

Cyproheptadine HCl USP is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride USP is a white to slightly yellowish crystalline solid, with a molecular weight of 350.89, which is soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform, and practically insoluble in ether. It is the sesquihydrate of 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is $C_{21}H_{21}N \cdot HCl$ and the structural formula of the anhydrous salt is:



$C_{21}H_{21}N \cdot HCl$ M.W. 350.89

Cyproheptadine hydrochloride USP is available for oral administration in 4 mg tablets. Inactive ingredients include: lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.

CLINICAL PHARMACOLOGY

Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.

Pharmacokinetics and Metabolism

After a single 4 mg oral dose of ¹⁴C-labelled cyproheptadine HCl in normal subjects, given as tablets, 2 to 20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of unchanged drug were present in the urine of patients on chronic 12 to 20 mg daily doses. The principle metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency.

Cyproheptadine HCl Tablets USP 4mg

NDC 24689-816-01

Cyproheptadine Hydrochloride Tablets, USP

4 mg

Rx only **100 Tablets**



Each tablet contains 4 mg of Cyproheptadine HCl, USP.

Usual Dosage: See package insert for complete prescribing information.

Store at 20°C to 25° (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a well-closed container as defined in the USP, with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured For:
Apnar Pharma LP
CHINO, CA 91710
USA

Rev.: 03/2018



N 3 24689-816-01 2

LOT:
EXP:

NDC 24689-816-10

Cyproheptadine Hydrochloride Tablets, USP

4 mg

Rx only **1000 Tablets**



Each tablet contains 4 mg of Cyproheptadine HCl, USP.

Usual Dosage: See package insert for complete prescribing information.

Store at 20°C to 25° (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a well-closed container as defined in the USP, with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured For:
Apnar Pharma LP
CHINO, CA 91710
USA

Rev.: 03/2018



N 3 24689-816-10 4

LOT:
EXP:

CYPROHEPTADINE HYDROCHLORIDE

cyproheptadine hydrochloride tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24689-816
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
CYPROHEPTADINE HYDROCHLORIDE (UNII: NJ82J0F8QC) (CYPROHEPTADINE - UNII:2YHB6175DO)	CYPROHEPTADINE HYDROCHLORIDE	4 mg

Inactive Ingredients

Ingredient Name	Strength
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	

MAGNESIUM STEARATE (UNII: 70097M6I30)

MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)

SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)

Product Characteristics

Color	white	Score	2 pieces
Shape	ROUND	Size	7mm
Flavor		Imprint Code	IT;68
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24689-816-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	05/21/2018	
2	NDC:24689-816-10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	05/21/2018	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA207555	05/15/2018	

Labeler - Apnar Pharma (079568229)

Establishment

Name	Address	ID/FEI	Business Operations
InvaTech Pharma Solutions LLC		078602180	manufacture(24689-816) , analysis(24689-816)

Revised: 5/2021

Apnar Pharma